Merck KGaA taps Selexis cell line tech for immuno-oncology antibodies

By Flora Southey

- Last updated on GMT


Related tags Escherichia coli Dna Merck kgaa

A Merck KGaA has signed a licensing agreement for Selexis’ SUREtechnology platform and its suspension-adapted CHO-K1 cell line.

Germany’s Merck KGaA will utilise the technology in its immuno-oncology antibody programme. The terms of the agreement were not disclosed.

According to Swiss-based mammalian cell line developer Selexis, the platform will provide Merck with advantages over traditional approaches, including speed, productivity, stability, and flexibility. 

The company said its SUREtechnology ​platform enables the production of virtually any recombinant protein, including those difficult to express in other systems. 

“Selexis’ SUREtechnology platform facilitates the rapid, stable and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to advance an immune-oncology antibody program,” ​a spokesperson told BioPharma-Reporter.

The technology produces a “high-expressing and stable research cell bank in 14 weeks from transfection, is not associated with gene amplifications, or viral transduction or potential future infections,” ​said the firm.

“It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization,” ​the spokesperson told us.

In the past year, Selexis has signed licensing deals for its SUREtechnology ​platform with Sanofi​, ASLAN Pharmaceuticals​, Pieris Pharmaceuticals​, Laboratorios Liomont and Progenics Pharmaceuticals.

Related topics Bio Developments Cell lines

Related news

Show more

Follow us